
Keytruda's fortress: Merck's patent-and-pricing empire under global scrutiny
An ICIJ investigation shows Merck’s Keytruda has become one of the world’s best-selling drugs not just because of therapeutic value but due to an expansive patent portfolio (more than 1,200 filings in 53 countries), lobbying, and pricing tactics that raise costs for patients worldwide while governments and insurers struggle to fund access; the report details price disparities, secrecy, accelerated approvals, and strategic moves like drug-dosing and product hopping that help Merck extend monopoly into the 2030s, with patients in India, Guatemala, the U.S. and elsewhere paying vast out-of-pocket or facing restricted access.


